A five-month classification case has reached NMPA-level review. If it leads to a formal catalog change, the consequences could extend from Chinese clinical trials to U.S. fundraising.
Could China Be Creating a Regulatory Category…
A five-month classification case has reached NMPA-level review. If it leads to a formal catalog change, the consequences could extend from Chinese clinical trials to U.S. fundraising.